Le Lézard
Classified in: Health
Subject: TRI

Job Research Foundation Announces 2024 Grant Recipient


NEW YORK, March 12, 2024 /PRNewswire/ -- The Job Research Foundation was established to underwrite research into Job Syndrome, also known as Autosomal Dominant Hyperimmunoglobulin E Syndrome (AD-HIES), a rare multisystem immunodeficiency disorder. The Foundation's main goal is to help advance research to improve treatments for patients suffering from the disease and eventually find a cure for Job Syndrome.

This year's recipient, Dr. Rasmus O. Bak, Associate Professor at Aarhus University in Denmark, will receive a grant totaling $200,000. The title of his research project is Next Generation CRISPR/Cas-based ex vivo Gene Editing of Autologous Hematopoietic Stem Cells as a Curative Treatment of Job Syndrome.

Since 2019 the Job Research Foundation has funded a total of 15 scientific research projects. The scientists hail from Australia, Germany, Spain, the US, the UK, and Denmark. Additionally, the researchers are from prestigious institutions including the Garvan Institute, Helmholtz Zentrum München, Hospital Infantil Universitario, Rockefeller University, Massachusetts General/Harvard Medical School, University of Newcastle, University of Pennsylvania, Boston Children's Hospital, University of Freiburg, Columbia University, and the DHHS/NIH. A list of the researchers and their projects can be viewed here https://www.jobresearchfoundation.org/grant-recipients.

The Job Research Foundation will start accepting the next round of grant applications in July 2024. Applications can be found on the website here: https://www.jobresearchfoundation.org/grant-application-process 

Job Syndrome was discovered in 1966 and is found in males and females worldwide. Visit https://www.jobresearchfoundation.org/ for additional information.

Media Contact:
Risa B. Hoag, GMG PR, 845-627-3000, [email protected] 

SOURCE Job Research Foundation


These press releases may also interest you

at 00:05
As May marks Preeclampsia Awareness Month, leading maternal health experts, preeclampsia survivors and industry leaders have come together on a new campaign, "Preeclampsia Prevention is Possible." The campaign elevates awareness of a major paradigm...

30 avr 2024
The report titled "Clinical Trial Analytics Services Market by Services (Clinical Data Analytics, Clinical Trial Data Management, Clinical Trial Planning & Monitoring), Component (Data Management & Integrity Services, Data Visualization &...

30 avr 2024
Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at the April ASCO Plenary Series, which was held online. Prof. Yuankai Shi, chief physician of...

30 avr 2024
Waverley Pharma Inc. ("Waverley Pharma" or the "Company") , a Canadian pharmaceutical company, is announcing a business update. As mentioned in the previous business update dated August 2, 2023, opportunities Waverley Pharma envisioned of marketing...

30 avr 2024
Feeding Matters is proud to celebrate the 6th annual PFD Awareness Month, which is recognized around the globe. This designation, initiated by Feeding...

30 avr 2024
Korea Ginseng Corp. US (KGCUS) aka JungKwanJang held a dedicated international seminar session on "Korean Ginseng: Safety, Efficacy And Neuroprotective Insights'' at the International Conference on the Science of Botanicals (ICSB) hosted by the...



News published on and distributed by: